Spyre Therapeutics, Inc.SYREEarnings & Financial Report
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted next-generation therapies for patients with rare, serious autoimmune and inflammatory diseases. It advances pipeline candidates through preclinical and early clinical stages to address unmet medical needs for global patient populations.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-44.1M
Net Profit
$-38.8M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$0.59
Spyre Therapeutics, Inc. Q2 FY2024 Financial Summary
Spyre Therapeutics, Inc. reported revenue of $0 for Q2 FY2024, with a net profit of $-38.8M (up 82.1% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-38.8M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2024 |
Spyre Therapeutics, Inc. Annual Revenue by Year
Spyre Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2024 | $0 |
Spyre Therapeutics, Inc. Quarterly Revenue & Net Profit History
Spyre Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $0 | — | $-69.0M | N/A |
| Q2 FY2024 | $0 | — | $-38.8M | N/A |
| Q1 FY2024 | $0 | — | $-43.9M | N/A |
| Q3 FY2023 | $0 | — | $-40.1M | N/A |
| Q2 FY2023 | $688.0K | +10.1% | $-217.1M | -31552.5% |
| Q1 FY2023 | $198.0K | -85.5% | $-18.4M | -9304.0% |
| Q3 FY2022 | $174.0K | -87.6% | $-18.2M | -10479.3% |
Income Statement
| Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $174000 | $198000 | $688000 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | -87.6% | -85.5% | 10.1% | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $91.6M | $52.5M | $243.5M | $207.3M | $487.6M | $436.1M | $421.1M | $608.5M |
| Liabilities | $24.0M | $18.8M | $253.6M | $65.6M | $81.9M | $61.7M | $93.7M | $90.7M |
| Equity | $67.6M | $33.7M | $-207.4M | $-245.4M | $152.3M | $374.4M | $327.4M | $517.8M |
Cash Flow
| Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.1M | $-17.6M | $-16.6M | $-34.6M | $-28.5M | $-62.2M | $-29.4M | $-37.2M |